Bigul

Neuland Laboratories stock surges 6%

The company has informed the stock exchange that the inspection at the facility has been completed, with no observations under Form 483
22-03-2024
Bigul

NEULAND LABORATORIES LTD. - 524558 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

We wish to inform you that the United States Food and Drug Administration ("US FDA") has inspected our Unit 1 manufacturing facility at Bonthapally, Hyderabad from 18th to 22nd March 2024. The inspection at Unit 1 by the US FDA has been successfully completed, with no observations under Form 483.
22-03-2024
Bigul

NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Intimation about Schedule of Analyst / Institutional Investor Meetings on 15/03/2024
11-03-2024
Bigul

NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Intimation about Schedule of Analyst / Institutional Investor Meetings on 07/03/2024
04-03-2024
Bigul

NEULAND LABORATORIES LTD. - 524558 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Issue of Letter of Confirmation in lieu of Share Certificate(s) reported lost / misplaced
26-02-2024
Bigul

NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Transcript of the Earnings call conducted on February 9, 2024
13-02-2024

Neuland Laboratories Q3 FY24 Results Live: Profit Rises by 166.43% YoY

Neuland Laboratories Q3 FY24 Results Live: Revenue increased by 45.9% YoY & profit increased by 166.43% YoY
11-02-2024
Next Page
Close

Let's Open Free Demat Account